Home » Newsletters » BioWorld Science

BioWorld Science

May 20, 2009

View Archived Issues

AT-7519 doses correlated with markers of CDK inhibition in solid tumor trial

PARP inhibition and antitumor activity seen with olaparib in phase I solid tumor study

PV-10 active as chemoablation in metastatic melanoma patients

OncoVEX(GM-CSF) active in unresectable metastatic melanoma

Discovery and development of PARP-1/2 inhibitor MK-4827 at Merck & Co. reported

Mutant FLT3 receptor inhibitor, ITRI-227, shows in vivo antitumor activity

Intrexon initiates phase Ib clinical trial of INcell-1001/AD-1001 in advanced melanoma

Takeda to acquire IDM Pharma in all-cash tender offer followed by merger

Northfield Laboratories to wind down business operations

MorphoSys and Daiichi Sankyo initiate two oncology-focused therapeutic antibody programs

OBT and GSK enter strategic alliance to develop cancer therapeutic antibodies

Asubio chooses Genedata's Expressionist to manage DNA array and molecular profiling data

FDA approves Johnson & Johnson's antipsychotic Risperdal Consta for bipolar I disorder

A.P. Pharma submits NDA to FDA for APF-530 in CINV

FDA accepts for filing MannKind's NDA for insulin product Afresa

Argenta elects drug to enter phase I studies under COPD collaboration with AstraZeneca

Clinical Data works with Dana-Farber Cancer Institute on FCGR3A gene variants

Shire presents guanfacine study results in ADHD

Novel mGluR5 receptor antagonists emerge from AstraZeneca R&D

Neurocrine reports results from Petal Study of elagolix for endometriosis pain

MUT-056399 targets Fabl enzyme for antistaphylococcal activity

Roche describes novel phosphatidylinositol 3-kinase inhibitors for cancer treatment

Exelixis claims the discovery of novel tropane compounds for cancer treatment

KBPA-101, a fully human antipseudomonas IgM, displays safety and tolerability in healthy volunteers

ZLB Plasma changes name to CSL Plasma

Mologen reports positive preliminary results from clinical trial with anticancer drug MGN-1703

Bayer receives Japanese approval for Nexavar for HCC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...